Smith & Nephew Earnings: Weak Orthopedics Growth Drags Down Quarterly Results
Smith & Nephew reported third-quarter underlying revenue growth of 3%, with outsize contribution from sports medicine joint repair that rose 11% year over year.
Smith & Nephew PLC ADR SNN
Bulls Say, Bears Say
Bulls
Smith & Nephew participates in the fast-growing sports medicine arena, thanks to its extensive arthroscopy portfolio.
Bears
Smith & Nephew's attempted shift to the lower-cost Syncera distribution model in the US was disappointing, which leaves the firm in a shaky competitive position for large-joint replacement in that market.
News
Smith+Nephew’s revolutionary CARTIHEAL™ AGILI-C™ Cartilage Repair Implant launches in Europe; to be featured at ICRS Summit in Portugal
MULTIMEDIA UPDATE: Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management
Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management
Natural design. Amplified: Smith+Nephew announces FDA 510(k) clearance and first surgical cases of LANDMARK™ Total Knee System
Smith+Nephew to showcase leading shoulder technologies for joint repair and reconstruction at ICSES 2026
Smith & Nephew Plc Announces Result of Cash Tender Offer for 2030 Bonds
Smith & Nephew Plc Announces Pricing of Cash Tender Offer for 2030 Bonds
Smith & Nephew Plc Announces Cash Tender Offer for 2030 Bonds Up To $250m
Trading Information
- Previous Close Price
- $30.92
- Day Range
- $30.71–31.11
- 52-Week Range
- $26.12–37.09
- Bid/Ask
- $25.68 / $36.00
- Shares Outstanding
- 418.52M
- Market Cap
- $12.99B
- Volume/Avg
- 1M / 2M
Key Statistics
- Price/Earnings (Normalized)
- 15.98
- Price/Sales
- 2.12
- Dividend Yield (Trailing)
- 2.57%
- Dividend Yield (Forward)
- 2.57%
- Dividend Payment Schedule
- May, Nov
- Total Yield
- 7.28%
Company Profile
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 40% of the UK-based firm's revenue comes from orthopedic products, and another 31% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the US, just over 30% is from other developed markets, and emerging markets account for the remainder.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Mid Core
- Total Number of Employees
- 17,000
- Website
- https://www.smith-nephew.com
Competitors
Valuation
Metric | SNN | ZBH | SYK |
|---|---|---|---|
Price/Earnings (Normalized) | 15.98 | 16.34 | 22.71 |
Price/Book Value | 2.52 | 1.60 | 5.26 |
Price/Sales | 2.12 | 2.44 | 4.76 |
Price/Cash Flow | 10.86 | 11.07 | 23.30 |
Price/Earnings
SNN
ZBH
SYK
Financial Strength
Metric | SNN | ZBH | SYK |
|---|---|---|---|
Quick Ratio | 1.11 | 0.63 | 1.07 |
Current Ratio | 2.14 | 1.46 | 2.18 |
Interest Coverage | 5.42 | 4.07 | 9.73 |
Quick Ratio
SNN
ZBH
SYK
Profitability
Metric | SNN | ZBH | SYK |
|---|---|---|---|
Return on Assets (Normalized) | 8.51% | 7.14% | 11.66% |
Return on Equity (Normalized) | 17.09% | 13.01% | 24.04% |
Return on Invested Capital (Normalized) | 11.66% | 9.36% | 15.46% |
Return on Assets
SNN
ZBH
SYK
Medical Devices Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Abbott Laboratories ABT | LOCK|R??%np | LOCK|y@yN | $191B | |||
| Medtronic PLC MDT | LOCK|&sYkK< | LOCK|l$Th | $130B | |||
| Stryker Corp SYK | LOCK|#M$WL?Sp | LOCK|n$! | $123B | |||
| Boston Scientific Corp BSX | LOCK|@%$@S>& | LOCK|$%#< | $65B | |||
| Edwards Lifesciences Corp EW | LOCK|z^kQk!L | LOCK|X@bW | $60B | |||
| GE HealthCare Technologies Inc Common Stock GEHC | LOCK|<^hJ?P | LOCK|#C | $38B | |||
| DexCom Inc DXCM | LOCK|CrCcq#R< | LOCK|^fy<# | $30B | |||
| Koninklijke Philips NV ADR PHG | LOCK|$V | LOCK|jL | $30B | |||
| Steris PLC STE | LOCK|^gf>x&S | LOCK|C$V< | $25B | |||
| Zimmer Biomet Holdings Inc ZBH | LOCK|LDQ&!&>^ | LOCK|&#s | $20B |
United States